Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients

• Main Authors: Tarek Z. El Baz, Osama A. Khamis, Amal El-Shehaby, Hussein Chahine, Ahmad Alaa Al-Din Ahmed, Mostafa A. Alsawasany
• Format: Article
• Language: English
• Published: SpringerOpen 2017-06-01
• Series: The Egyptian Heart Journal
• Subjects: Vascular calcification; Osteoprotegerin; Hemodialysis patients
• Online Access: http://www.sciencedirect.com/science/article/pii/S111026081630093X

Background: Uremia is a vasculopathic process, and both cardiac calcification and vascular calcification seen from the early stages of chronic kidney disease. Osteoprotegerin could play a crucial role in atherosclerotic plaque formation, maturation and calcification. The goal of this study was to determine the relationship of serum osteoprotegerin with vascular calcification in patients with end stage kidney disease who were maintained on regular hemodialysis. Methods: Sixty clinically stable chronic renal failure patients undergoing regular hemodialysis were enrolled in this cross sectional study. Thirty patients (mean age 56.7 ± 10.5 years) with abdominal aortic calcification were selected by basal abdominal X-ray who underwent multi-slice computerized tomography scan to measure coronary artery calcification score; and thirty patients (mean age 56.5 ± 8.4 years) without abdominal aortic calcification. All patients were evaluated by serum calcium, phosphorus, albumin, lipid profile, intact parathyroid hormone (iPTH), serum creatinine, serum urea, serum uric acid, serum C-reactive protein, and hemoglobin. Serum osteoprotegerin samples were collected before dialysis and estimated by the ELISA kit. Results: Serum osteoprotegerin level was significantly higher in patients with vascular calcification than in those without calcifications. Serum osteoprotegerin correlated positively with serum phosphorus, calcium phosphorus product, alkaline phosphatase, iPTH, C-reactive protein, serum uric acid, low-density lipoprotein (LDL) and left ventricular mass index (LVMI) (p < 0.005), and negatively with hemoglobin, ejection fraction (p < 0.005) and HDL (p < 0.05). Conclusions: These findings suggest that osteoprotegerin may be involved in the development of vascular calcification in hemodialysis patients.